Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

(

OPTIMAL

)

ITN Protocol #:

ITN056ST

Branded Name:

OPTIMAL

ClinicalTrials.Gov ID:

NCT02533180

Treatment Protocol #:

Therapeutic Area:

Transplantation

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Scientist

PPD Lead Monitor

Study Personnel:

Protocol Chair

James Markmann, MD PhD James.Markmann@pennmedicine.upenn.edu

Work:

215-662-4083

Protocol Chair

Michele DesMarais mdesmarais@immunetolerance.org

Work:

415-420-4250

Protocol Chair

Geo Gaile ggaile@immunetolerance.org

Work:

415-854-7485

Protocol Chair

Juliete Francisco Da Silva, PhD jsilva@immunetolerance.org

Work:

205-960-1065

Protocol Chair

Sai Kanaparthi skanaparthi@immunetolerance.org

Work:

(240)235-6101

Protocol Chair

Sindhu Chandran, MD schandran@immunetolerance.org

Work:

415-610-4284

Protocol Chair

Meredith Brown Shifflett brownmeri@niaid.nih.gov

Work:

(240) 627-3483

Protocol Chair

Theresa Scocca Theresa_Scocca@rhoworld.com

Work:

919-595-6312

Protocol Chair

Cheryl Wilmoth cheryl.wilmoth@ppdi.com

Work:

1 336-244-8947